Meet Our Staff

Crystal Watson, ATHN's President and CEO has over 25 years of experience working in the blood disorders community in both government and nonprofit organizations. Since joining ATHN in 2008, Crystal has successfully championed the evolution of the technology and infrastructure underpinning the national database now being used to support research and surveillance.

Prior to joining ATHN, Crystal was with the CDC in the Division of Blood Disorders and the National Center for Public Health Informatics and spent 10-years with Hemophilia of Georgia. She has a Bachelor of Science degree in Social Work from the University of North Carolina.

Moses Miles is the Chief Operating Officer of the American Thrombosis and Hemostasis Network. In this role he is responsible for the day-to-day activities of the organization and ensuring the execution of ATHN’s mission. He has more than 30 years’ experience in information and healthcare technology in commercial, US federal and US state environments. Moses is a former Senior Manager of Deloitte Consulting and the former Chief Architect of the State of Georgia where he was responsible for setting technology policy and standards for the state’s agencies.

Michael Niekamp is responsible for ATHN’s finance and human resource functions. He brings more than 20 years of experience in financial leadership in the nonprofit healthcare space, including senior leadership roles with the Lung Cancer Research Foundation, Cohen Veterans Network, National Multiple Sclerosis Society, and The Leukemia & Lymphoma Society. Michael is a graduate of Siena College in Loudonville, NY.

As Chief Science Officer (CSO) for ATHN, Tammuella Chrisentery-Singleton, MD, works at the strategic and policy level to inform the scientific direction of ATHN. She works across the organization to define, develop, and implement ATHN’s science and research capabilities as well as to ensure ATHN’s commitment to public health.

Dr. Singleton is board-certified in general pediatrics and pediatric hematology/oncology. Her areas of special interest include sickle cell disease, rare blood disorders, gene therapy, and musculoskeletal ultrasound in hemophilia patients. She has authored numerous publications and led more than 60 clinical trials and research studies—including serving as the principal investigator for ATHN 16: Safety of SEVENFACT® for the Treatment of Bleeding Events in Patients with Hemophilia A or B with Inhibitor.

Before joining ATHN, Dr. Singleton was the Chief of Pediatric Hematology and Director of the Hemophilia Treatment Center for the Mississippi Center for Advanced Medicine. She also previously served as the Chief of Pediatric Hematology and Oncology, the Director of the Sickle Cell Center of South Louisiana, and the Associate Director of the Louisiana Center for Bleeding and Clotting Disorders at the Tulane University School of Medicine/Tulane Hospital for Children.